ストックスクリーナーアプリを入手
16.85
4.92%
0.79
アフターアワーズ：
16.76
-0.09
-0.53%
前日終値:
$16.06
開ける：
$16.19
24時間の取引高:
3.85M
Relative Volume:
1.34
時価総額：
$12.54B
収益：
$220.00K
当期純損益:
$-746.08M
株価収益率:
-16.73
EPS:
-1.0074
ネットキャッシュフロー:
$-211.81M
1週間 パフォーマンス:
-4.53%
1か月 パフォーマンス:
-5.44%
6か月 パフォーマンス:
-36.03%
1年 パフォーマンス:
-23.76%
1日の値動き範囲:
$15.66
$17.02
1週間の範囲:
$15.66
$17.86
52週間の値動き範囲:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
SMMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.85 | 11.96B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.14 | 112.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.33 | 77.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.37 | 50.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
365.46 | 46.97B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.64 | 36.99B | 4.98B | 69.59M | 525.67M | 0.5197 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-17 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-09-17 | 開始されました | Barclays | Underweight |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Neutral |
| 2025-07-01 | 開始されました | UBS | Buy |
| 2025-06-11 | 開始されました | Leerink Partners | Underperform |
| 2025-03-26 | アップグレード | Citigroup | Neutral → Buy |
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | Goldman | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-07 | 開始されました | Citigroup | Buy |
| 2024-03-26 | 開始されました | Stifel | Buy |
| 2018-06-28 | ダウングレード | Janney | Buy → Neutral |
| 2018-05-02 | 開始されました | Janney | Buy |
| 2018-04-12 | 繰り返されました | Needham | Buy |
| 2018-02-13 | 開始されました | BTIG Research | Buy |
| 2018-01-04 | 開始されました | SunTrust | Buy |
| 2017-12-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-05 | 繰り返されました | Needham | Buy |
| 2016-09-16 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-30 | 開始されました | Needham | Buy |
| 2015-03-30 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Summit Therapeutics Inc (SMMT) 最新ニュース
Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio? - Benzinga
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation - MSN
(SMMT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Is Summit Therapeutics (SMMT) Building a Durable Oncology Combination Platform With Ivonescimab’s Expanding Reach? - Sahm
Buyout Rumor: Will Summit Therapeutics Inc outperform the market in YEAR2025 Major Catalysts & Long-Term Growth Stock Strategies - baoquankhu1.vn
Summit Therapeutics Advances Ivonescimab Into Key Phase 3 Test in Metastatic Colorectal Cancer - TipRanks
Assessing Summit Therapeutics (SMMT) Valuation After Ivonescimab FDA Filing And New GSK Trial Collaboration - Sahm
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Summit Therapeutics PLC $SMMT Shares Purchased by APEIRON CAPITAL Ltd - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Nasdaq 100 Index Biotech Position - Kalkine Media
Summit Therapeutics stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Can Summit Therapeutics Inc. be the next market leaderBull Market Opportunities & Breakout Portfolio Performance - bollywoodhelpline.com
Rate Cut: Will Summit Therapeutics Inc benefit from AI trends2025 Macro Impact & Weekly Return Optimization Alerts - baoquankhu1.vn
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge - Yahoo Finance
Citizens reiterates Market Outperform rating on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 13.4%What's Next? - MarketBeat
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows - TechStock²
2 Biotech Stocks That Could Soar This Year - The Globe and Mail
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC - Business Wire
GSK Collaborates with Summit Therapeutics on Cancer Treatment Tr - GuruFocus
Summit Therapeutics Files Marketing Application for Lung Cancer Therapy - 富途牛牛
Summit Therapeutics (SMMT) Seeks FDA Approval for Innovative Lun - GuruFocus
Summit Therapeutics partners with GSK for cancer drug combination trial - StreetInsider
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) - Business Wire
Summit Therapeutics files FDA application for cancer drug ivonescimab - StreetInsider
Summit Therapeutics Inc. (SMMT): Investor Outlook on a Biotech Stock with 66.79% Upside Potential - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Grants Stock Options to New Employees - GuruFocus
Cantor Fitzgerald reaffirms overweight rating on Summit Therapeutics (SMMT) before key 2026 catalyst - MSN
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Summit Therapeutics gives 17 new hires options on 214,331 shares - Stock Titan
How Summit Therapeutics Inc. stock valuations compare to rivalsJuly 2025 Technicals & Free Community Supported Trade Ideas - ulpravda.ru
Can Summit Therapeutics Inc. stock continue upward trendPrice Action Trading & Accelerated Earnings Growth - ulpravda.ru
A Look At Summit Therapeutics (SMMT) Valuation After Recent Share Price Strength - Yahoo Finance
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Price-Driven Insight from (SMMT) for Rule-Based Strategy - Stock Traders Daily
Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst - Finviz
Summit Therapeutics Earnings Notes - Trefis
15 Best Stocks Under $25 to Buy Now - Insider Monkey
Farther Finance Advisors LLC Makes New $1.14 Million Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Capricorn Fund Managers Ltd Takes $10.25 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Closing the Year With Gratitude and Shared Purpose – Summit Therapeutics - Oncodaily
Summit Therapeutics Inc. (SMMT) Stock Analysis: An 83.78% Potential Upside In Biotech - DirectorsTalk Interviews
Summit Therapeutics Shares Slip Following Mixed Results from Lung Cancer Trial - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Summit Therapeutics Inc. stock a defensive play in 20252025 Price Momentum & Free Community Consensus Stock Picks - Улправда
How Summit Therapeutics Inc. stock compares to industry benchmarks2025 Big Picture & Long Hold Capital Preservation Plans - ulpravda.ru
Summit Therapeutics Inc (SMMT) 財務データ
収益
当期純利益
現金流量
EPS
5.17%
4.40%
大文字化:
|
ボリューム (24 時間):